Emerging and future therapies for nonalcoholic steatohepatitis in adults

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 14, 2016, Pages 1937-1946

  Mintziori, Gesthimani ^a   Polyzos, Stergios A ^a  

^a Ippokration Hospital   (Greece)

Author keywords

Fibrosis; inflammation; insulin resistance; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; steatosis; thiazolidinediones; treatment; vitamin E

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ALPHA TOCOPHEROL; ANTIDIABETIC AGENT; ANTIFIBROTIC AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; COTRANSPORTER; FARNESOID X RECEPTOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; OBETICHOLIC ACID; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROBIOTIC AGENT; SODIUM; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID; CHENODEOXYCHOLIC ACID; GLUCAGON LIKE PEPTIDE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

HUMAN; LIVER FIBROSIS; LONG TERM EXPOSURE; NONALCOHOLIC FATTY LIVER; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; TREATMENT PLANNING; ADULT; ANALOGS AND DERIVATIVES; DRUG DESIGN; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE;

ADULT; CHENODEOXYCHOLIC ACID; DRUG DESIGN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; THIAZOLIDINEDIONES; VITAMIN E;

EID: 84988354477     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2016.1225727     Document Type: Review

References (100)

1. Y.Fazel, A.B.Koenig, M.Sayiner, et al. Epidemiology and natural history of nonalcoholic fatty liver disease. Metabolism. 2016;65:1017–1025.
2. R.S.Khan, P.N.Newsome Non-alcoholic fatty liver disease and liver transplantation. Metabolism. 2016;65:1208–1223.
3. S.A.Polyzos, J.Kountouras, C.Zavos. Nonalcoholic fatty liver disease:the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med. 2009;72:299–314.
4. D.E.Kleiner, E.M.Brunt, M.Van Natta, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.
5. M.E.Rinella. Nonalcoholic fatty liver disease:a systematic review. JAMA. 2015;313:2263–2273.• An updated systematic review for NAFLD.
6. G.Marchesini, M.Roden, R.Vettor, et al. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016; 59:1121–1140.•• The most recent clinical practice guidelines for NAFLD management.
7. S.A.Harrison. NASH, from diagnosis to treatment:where do we stand? Hepatology. 2015;62:1652–1655.
8. S.A.Polyzos, J.Kountouras, C.Zavos, et al. Nonalcoholic fatty liver disease:multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol. 2012;46:272–284.
9. S.Sauer. Ligands for the nuclear peroxisome proliferator-activated receptor gamma. Trends Pharmacol Sci. 2015;36:688–704.
10. S.A.Polyzos, C.S.Mantzoros. Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones:a systematic review. Metabolism. 2016;65:1297–1306.
11. U.Smith. Pioglitazone:mechanism of action. Int J Clin Pract Suppl. 2001;121:13–18.
12. N.Chalasani, Z.Younossi, J.E.Lavine, et al. The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023.
13. S.Singh, R.Khera, A.M.Allen, et al. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis:a systematic review and network meta-analysis. Hepatology. 2015;62:1417–1432.•• A network meta-analysis providing evidence for comparative effectiveness for medications investigated in NASH.
14. G.Musso, M.Cassader, F.Rosina, et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD):a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55:885–904.
15. S.E.Mahady, A.C.Webster, S.Walker, et al. The role of thiazolidinediones in non-alcoholic steatohepatitis – a systematic review and meta analysis. J Hepatol. 2011;55:1383–1390.
16. K.Cusi, B.Orsak, F.Bril, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus:a randomized, controlled trial. Ann Intern Med. 2016. doi:10.7326/M15-1774.•• A well-conducted RCT with an open-label extension study on the long-term safety and efficacy of pioglitazone in NASH.
17. Z.Omer, S.Cetinkalp, M.Akyildiz, et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2010;22:18–23.
18. D.Torres, F.Jones, J.Shaw, et al. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis (NASH):a 12 month-randomized, prospective, open-label trial. Hepatology. 2011;54:1631–1639.
19. G.Lutchman, A.Modi, D.E.Kleiner, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology. 2007;46:424–429.
20. C.K.Argo, J.C.Iezzoni, A.M.Al-Osaimi, et al. Thiazolidinediones for the treatment in NASH:sustained benefit after drug discontinuation? J Clin Gastroenterol. 2009;43:565–568.
21. S.E.Nissen, K.Wolski. Rosiglitazone revisited:an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. ArchInternMed. 2010;170:1191–1201.
22. J.D.Lewis, A.Ferrara, T.Peng, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone:interim report of a longitudinal cohort study. Diabetes Care. 2011;34:916–922.
23. S.Gawrieh, N.Chalasani. Pharmacotherapy for nonalcoholic fatty liver disease. Semin Liver Dis. 2015;35:338–348.
24. A.J.Sanyal, N.Chalasani, K.V.Kowdley, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–1685.•• A well-conducted RCT providing evidence for the efficacy of pioglitazone or vitamin E vs. placebo in adult NASH patients.
25. J.E.Lavine, J.B.Schwimmer, M.L.Van Natta, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents:the TONIC randomized controlled trial. JAMA. 2011;305:1659–1668.•• A well-conducted RCT providing evidence for the efficacy of metformin or vitamin E vs. placebo in children and adolescents with NASH.
26. S.M.Lippman, E.A.Klein, P.J.Goodman, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers:the selenium and vitamin E cancer prevention trial (SELECT). JAMA. 2009;301:39–51.
27. E.R.Miller3rd, R.Pastor-Barriuso, D.Dalal, et al. Meta-analysis:high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46.
28. C.O.Zein, L.M.Yerian, P.Gogate, et al. Pentoxifylline improves nonalcoholic steatohepatitis:a randomized placebo-controlled trial. Hepatology. 2011;54:1610–1619.• A well-conducted RCT providing evidence for the efficacy of pentoxifylline in NASH patients.
29. Y.Shirakami, M.Shimizu, M.Kubota, et al. Pentoxifylline prevents nonalcoholic steatohepatitis-related liver pre-neoplasms by inhibiting hepatic inflammation and lipogenesis. Eur J Cancer Prev. 2016;25:206–215.
30. N.Baniasadi, F.Salajegheh, A.Pardakhty, et al. Effects of pentoxifylline on non-alcoholic steatohepatitis:a randomized, double-blind, placebo-controlled trial in Iran. Hepat Mon. 2015;15:e32418.
31. L.Adorini, M.Pruzanski, D.Shapiro. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today. 2012;17:988–997.
32. S.Cipriani, A.Mencarelli, G.Palladino, et al. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res. 2010;51:771–784.
33. M.Wagner, G.Zollner, M.Trauner. Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB:new insights into hepatic inflammation. Hepatology. 2008;48:1383–1386.
34. B.A.Neuschwander-Tetri, R.Loomba, A.J.Sanyal, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT):a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965.•• A well-conducted RCT providing evidence for the efficacy of obeticholic acid in NASH patients.
35. W.N.HannahJr., S.A.Harrison. Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease. Clin Liver Dis. 2016;20:339–350.
36. S.Zelber-Sagi, A.Kessler, E.Brazowsky, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006;4:639–644.
37. S.A.Harrison, W.Fecht, E.M.Brunt, et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis:a randomized, prospective trial. Hepatology. 2009;49:80–86.
38. R.Poupon, Y.Chretien, R.E.Poupon, et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet. 1987;1:834–836.
39. B.Oh, W.S.Choi, S.B.Park, et al. Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver:a multi-centre, randomised, double-blinded, placebo-controlled trial. Int J Clin Pract. 2016;70:302–311.
40. Z.Xiang, Y.P.Chen, K.F.Ma, et al. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis:a systematic review. BMC Gastroenterology. 2013;13:140.
41. K.Tziomalos, V.G.Athyros, P.Paschos, et al. Nonalcoholic fatty liver disease and statins. Metabolism. 2015;64:1215–1223.
42. V.G.Athyros, K.Tziomalos, T.D.Gossios, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study:a post-hoc analysis. Lancet. 2010;376:1916–1922.•• A well-conducted study providing evidence for the long-term efficacy and safety of statins in patients with abnormal liver function tests.
43. H.M.Parker, N.A.Johnson, C.A.Burdon, et al. Omega-3 supplementation and non-alcoholic fatty liver disease:a systematic review and meta-analysis. J Hepatol. 2012;56:944–951.
44. T.R.Haque, A.Barritt. Intestinal microbiota in liver disease. Best Pract Res Clin Gastroenterol. 2016;30:133–142.
45. S.F.Solga, G.Buckley, J.M.Clark, et al. The effect of a probiotic on hepatic steatosis. J Clin Gastroenterol. 2008;42:1117–1119.
46. V.W.Wong, G.L.Won, A.M.Chim, et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol. 2013;12:256–262.
47. X.Gao, Y.Zhu, Y.Wen, et al. Efficacy of probiotics in nonalcoholic fatty liver disease in adult and children:a meta-analysis of randomized controlled trials. Hepatol Res. 2016. doi:10.1111/hepr.12671.
48. Y.Morita, T.Ueno, N.Sasaki, et al. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes. Hepatogastroenterology. 2005;52:1338–1343.
49. M.J.Armstrong, D.Barton, P.Gaunt, et al. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN):study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open. 2013;3:e003995.
50. M.J.Armstrong, P.Gaunt, G.P.Aithal, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN):a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679–690.•• A well-conducted RCT providing evidence for the efficacy of liraglutide in NASH patients.
51. L.J.Carbone, P.W.Angus, N.D.Yeomans. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease:a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:23–31.
52. X.Ding, N.K.Saxena, S.Lin, et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology. 2006;43:173–181.
53. J.E.Mells, P.P.Fu, S.Sharma, et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol. 2012;302:G225–35.
54. J.Cui, L.Philo, P.Nguyen, et al. Sitagliptin versus placebo in the treatment of nonalcoholic fatty liver disease:a randomized controlled trial. J Hepatol. 2016;65:369–376.
55. B.Finan, B.Yang, N.Ottaway, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21:27–36.
56. T.Ohki, A.Isogawa, N.Toda, et al. Effectiveness of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, as a second-line treatment for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus who do not respond to incretin-based therapies including glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors. Clin Drug Investig. 2016;36:313–319.
57. L.S.Higgins, C.S.Mantzoros. The development of INT131 as a selective PPARgamma modulator:approach to a safer insulin sensitizer. PPAR Res. 2008;2008:936906.
58. F.L.Dunn, L.S.Higgins, J.Fredrickson, et al. Selective modulation of PPARgamma activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with type 2 diabetes. J Diabetes Complications. 2011;25:151–158.
59. A.M.DePaoli, L.S.Higgins, R.R.Henry, et al. Can a selective PPARgamma modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? Diabetes Care. 2014;37:1918–1923.
60. V.Ratziu, S.A.Harrison, S.Francque, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150:1147–1159. e5.• A Phase 2b study providing evidence for the efficacy of elafibranor in NASH patients.
61. S.Heeboll, M.Kreuzfeldt, S.Hamilton-Dutoit, et al. Placebo-controlled, randomised clinical trial:high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol. 2016;51:456–464.
62. C.Iacobini, S.Menini, C.Ricci, et al. Galectin-3 ablation protects mice from diet-induced NASH:a major scavenging role for galectin-3 in liver. J Hepatol. 2011;54:975–983.
63. P.G.Traber, H.Chou, E.Zomer, et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One. 2013;8:e75361.
64. T.Aoyama, Y.H.Paik, S.Watanabe, et al. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis:GKT137831 as a novel potential therapeutic agent. Hepatology. 2012;56:2316–2327.
65. S.Friedman, A.Sanyal, Z.Goodman, et al. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis:CENTAUR phase 2b study design. Contemp Clin Trials. 2016;47:356–365.• A Phase 2b study providing evidence for the efficacy of cenicriviroc in NASH patients.
66. V.Barry-Hamilton, R.Spangler, D.Marshall, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16:1009–1017.
67. M.Enjoji, K.Machida, M.Kohjima, et al. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Lipids Health Dis. 2010;9:29.
68. S.C.Lin, B.Ang, C.Hernandez, et al. Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis:a secondary analysis of the MOZART trial. Therap Adv Gastroenterol. 2016;9:152–161.
69. R.Loomba, C.B.Sirlin, B.Ang, et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis:assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology. 2015;61:1239–1250.
70. A.Leikin-Frenkel, A.Gonen, A.Shaish, et al. Fatty acid bile acid conjugate inhibits hepatic stearoyl coenzyme A desaturase and is non-atherogenic. Arch Med Res. 2010;41:397–404.
71. R.Safadi, F.M.Konikoff, M.Mahamid, et al. The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2085–2091. e1.
72. S.A.Polyzos, J.Kountouras, C.S.Mantzoros. Adipokines in nonalcoholic fatty liver disease. Metabolism. 2016;65:1062–1079.
73. S.A.Polyzos, C.S.Mantzoros. Leptin in health and disease:facts and expectations at its twentieth anniversary. Metabolism. 2015;64:5–12.
74. S.A.Polyzos, K.N.Aronis, J.Kountouras, et al. Circulating leptin in non-alcoholic fatty liver disease:a systematic review and meta-analysis. Diabetologia. 2015;59:30–43.
75. S.A.Polyzos, K.A.Toulis, D.G.Goulis, et al. Serum total adiponectin in nonalcoholic fatty liver disease:a systematic review and meta-analysis. Metabolism. 2011;60:313–326.
76. S.A.Polyzos, J.Kountouras, C.S.Mantzoros. Leptin in nonalcoholic fatty liver disease:a narrative review. Metabolism. 2015;64:60–78.
77. S.A.Polyzos, J.Kountouras, C.Zavos, et al. The potential adverse role of leptin resistance in nonalcoholic fatty liver disease:a hypothesis based on critical review of literature. J Clin Gastroenterol. 2011;45:50–54.
78. A.Xu, Y.Wang, H.Keshaw, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91–100.
79. S.A.Polyzos, J.Kountouras, C.Zavos, et al. The role of adiponectin in the pathogenesis and treatment of nonalcoholic fatty liver disease. Diabetes Obes Metab. 2010;12:365–383.
80. S.A.Polyzos, J.Kountouras, C.Zavos. Adiponectin as a potential therapeutic agent for nonalcoholic steatohepatitis. Hepatol Res. 2010;40:446–447.
81. S.A.Polyzos, J.Kountouras, C.Zavos. Adiponectin in non-alcoholic fatty liver disease treatment:therapeutic perspectives and unresolved dilemmas. Int J Clin Pract. 2011;65:373–374.
82. F.J.Barreyro, S.Holod, P.V.Finocchietto, et al. The pan-caspase inhibitor emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015;35:953–966.
83. N.Itoh, Y.Nakayama, M.Konishi. Roles of FGFs as paracrine or endocrine signals in liver development, health, and disease. Front Cell Dev Biol. 2016;4:30.
84. J.Xu, D.J.Lloyd, C.Hale, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009;58:250–259.
85. K.T.Shenoy, L.K.Balakumaran, P.Mathew, et al. Metadoxine versus placebo for the treatment of non-alcoholic steatohepatitis:a randomized controlled trial. J Clin Exp Hepatol. 2014;4:94–100.
86. T.Wada, H.Kenmochi, Y.Miyashita, et al. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology. 2010;151:2040–2049.• An experimental study providing promising evidence for the therapeutic potential of spironolactone in NASH.
87. T.Wada, Y.Miyashita, M.Sasaki, et al. Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet. Am J Physiol Endocrinol Metab. 2013;305:E1415–25.
88. S.A.Polyzos, J.Kountouras, E.Zafeiriadou, et al. Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease. J Renin Angiotensin Aldosterone Syst. 2011;12:498–503.
89. S.A.Polyzos, C.S.Mantzoros. Nonalcoholic fatty future disease. Metabolism. 2016;65:1007–1016.
90. M.R.Charlton, J.M.Burns, R.A.Pedersen, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249–1253.
91. Z.M.Younossi, M.Otgonsuren, L.Henry, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62:1723–1730.
92. S.A.Polyzos, C.S.Mantzoros. Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism. 2014;63:161–167.
93. E.Buzzetti, M.Pinzani, E.A.Tsochatzis. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–1048.
94. S.A.Polyzos, J.Kountouras, C.Zavos. The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in nonalcoholic fatty liver disease. Hippokratia. 2009;13:127.
95. S.A.Polyzos, C.S.Mantzoros. An update on the validity of irisin assays and the link between irisin and hepatic metabolism. Metabolism. 2015;64:937–942.
96. M.Chung, J.Ma, K.Patel, et al. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health:a systematic review and meta-analysis. Am J Clin Nutr. 2014;100:833–849.
97. S.A.Polyzos, J.Kountouras, A.Papatheodorou, et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism. 2013;62:121–126.
98. S.A.Polyzos, J.Kountouras, G.Deretzi, et al. The emerging role of endocrine disruptors in pathogenesis of insulin resistance:a concept implicating nonalcoholic fatty liver disease. Curr Mol Med. 2012;12:68–82.
99. C.S.Voican, G.Perlemuter. Insulin resistance and oxidative stress:two therapeutic targets in non-alcoholic steatohepatitis. J Hepatol. 2011;54:388–391.
100. B.M.Arendt, J.P.Allard. Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease:is the combination required? Am J Gastroenterol. 2011;106:78–80.•• A study providing evidence for combined treatment in NASH.